Publication: 4434

Publication: 4434

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: N Engl J Med vol 392 (7) 653-65

Year:: 2025
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 15

Parents:: 4156
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:: Health Outcomes

Pharmas:: Exelixis
Grants:: U10CA180821, U10CA180882, UG1CA189856, UG1CA189804, UG1CA232760, UG1CA233180, UG1CA233290, UG1CA233329, UG1CA233331, UG1CA233339, U10CA180820 (ECOG-ACRIN), U10CA180868 (NRG Oncology), U10CA180888 (SWOG);

Corr. Author:
Authors:: Jennifer A Chan Susan Geyer Tyler Zemla Michael V Knopp Spencer Behr Sydney Pulsipher Fang-Shu Ou Amylou C Dueck Jared Acoba Ardaman Shergill Edward M Wolin Thorvardur R Halfdanarson Bhavana Konda Nikolaos A Trikalinos Bernard Tawfik Nitya Raj Shagufta Shaheen Namrata Vijayvergia Arvind Dasari Jonathan R Strosberg Elise C Kohn Matthew H Kulke Eileen M O'Reilly Jeffrey A Meyerhardt

Networks:: CA824, FL065, HAWAII, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NEWMEXICO, NY021

Study: Alliance-A021602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: